We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 628.57%
This Fund
S&P 500
This Quarter Est. Return
+24.59%
1 Year Est. Return
+628.57%
3 Year Est. Return
+1,083.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$697M
AUM Growth
+$145M
Cap. Flow
+$37.3M
Cap. Flow %
5.35%
Top 10 Hldgs %
75.59%
Holding
24
New
3
Increased
13
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
TRVI icon
Trevi Therapeutics
TRVI
+$15.3M
2
CELC icon
Celcuity
CELC
+$10.2M
3
SGMT icon
Sagimet Biosciences
SGMT
+$10.1M
4
IMMX icon
Immix Biopharma
IMMX
+$8.95M
5
VIR icon
Vir Biotechnology
VIR
+$7.33M

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$24.1M
2
OVID icon
Ovid Therapeutics
OVID
+$9.04M
3
ALMS
Alumis Inc
ALMS
+$6.67M
4
IVVD icon
Invivyd
IVVD
+$3.21M
5
ABVX
Abivax
ABVX
+$2.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
1
Amylyx Pharmaceuticals
AMLX
$3.78B
$83M 11.91%
4,624,101
+274,216
+6% +$4.24M
ALMS
2
Alumis Inc
ALMS
$1.47B
$82M 11.76%
2,915,443
-286,632
-9% -$6.67M
ABVX
3
Abivax
ABVX
$9.95B
$69.1M 9.91%
518,865
-23,831
-4% -$2.7M
PCVX icon
4
Vaxcyte
PCVX
$9.1B
$49.6M 7.11%
852,914
+28,382
+3% +$1.54M
IMMX icon
5
Immix Biopharma
IMMX
$985M
$48M 6.89%
4,658,429
+964,844
+26% +$8.95M
PHVS icon
6
Pharvaris
PHVS
$2.5B
$45.4M 6.52%
1,314,122
+112,720
+9% +$3.41M
JAZZ icon
7
Jazz Pharmaceuticals
JAZZ
$16.1B
$38.8M 5.56%
160,938
-2,023
-1% -$443K
CELC icon
8
Celcuity
CELC
$4.72B
$38.7M 5.55%
370,318
+88,414
+31% +$10.2M
IRON icon
9
Disc Medicine
IRON
$3.05B
$38.4M 5.5%
524,730
+74,804
+17% +$5.14M
CADL icon
10
Candel Therapeutics
CADL
$992M
$34M 4.88%
3,303,686
+407,098
+14% +$3.08M
XFOR icon
11
X4 Pharmaceuticals
XFOR
$401M
$32.6M 4.67%
6,973,343
+516,697
+8% +$2.12M
MNPR icon
12
Monopar Therapeutics
MNPR
$796M
$28.9M 4.14%
311,976
-33,650
-10% -$2.08M
DYN icon
13
Dyne Therapeutics
DYN
$4.66B
$23.5M 3.37%
1,057,493
+90,884
+9% +$1.69M
TRVI icon
14
Trevi Therapeutics
TRVI
$2.43B
$19.6M 2.81%
+1,052,043
New +$15.3M
ZURA icon
15
Zura Bio
ZURA
$563M
$12.4M 1.78%
2,101,119
+1,361,159
+184% +$6.48M
SGMT icon
16
Sagimet Biosciences
SGMT
$679M
$11.4M 1.64%
+1,479,918
New +$10.1M
OCS icon
17
Oculis Holding
OCS
$676M
$9.5M 1.36%
684,880
+168,119
+33% +$3.82M
IKT icon
18
Inhibikase Therapeutics
IKT
$352M
$7.85M 1.13%
3,869,056
+5,611
+0.1% +$10K
VIR icon
19
Vir Biotechnology
VIR
$1.94B
$7.85M 1.13%
+770,643
New +$7.33M
IVVD icon
20
Invivyd
IVVD
$246M
$7.32M 1.05%
8,392,288
-2,556,796
-23% -$3.21M
ANRO icon
21
Alto Neuroscience
ANRO
$1.43B
$4.82M 0.69%
182,829
+93,830
+105% +$2.17M
MSLE
22
Satellos Bioscience
MSLE
$193M
$2.72M 0.39%
350,000
– –
OVID icon
23
Ovid Therapeutics
OVID
$543M
$1.78M 0.26%
663,060
-3,503,606
-84% -$9.04M
COGT icon
24
Cogent Biosciences
COGT
$6.06B
– –
-626,635
Closed -$24.1M

Similar funds

DE
DV Equities Chicago, Illinois $698M AUM
MAA
Mraz Amerine & Associates Modesto, California $697M AUM 19.37% 1-Year Est. Return
PGAM
Princeton Global Asset Management Princeton, New Jersey $698M AUM 31.09% 1-Year Est. Return
FMN
Financial Management Network Mission Viejo, California $697M AUM 21.37% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $698M AUM 23.16% 1-Year Est. Return
CA
Crane Advisory Fullerton, California $697M AUM 12.55% 1-Year Est. Return
FA
Fiducient Advisors Chicago, Illinois $698M AUM 20.16% 1-Year Est. Return
BWM
Brickley Wealth Management San Mateo, California $696M AUM 25.84% 1-Year Est. Return

Saturn V Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Saturn V Capital Management held 24 positions worth $697M, up 26% from $552M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Saturn V Capital Management deployed $37.3M of net new capital in Q2 2026, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was Trevi Therapeutics: 1,052,043 shares worth $19.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ovid Therapeutics, an estimated $9.04M trimmed.

  • Saturn V Capital Management's largest Q2 2026 buy was Trevi Therapeutics: 1,052,043 shares worth $19.6M.
  • Saturn V Capital Management added most to Celcuity in Q2 2026, an estimated $10.2M increase.
  • Saturn V Capital Management's biggest Q2 2026 reduction was Ovid Therapeutics, cutting an estimated $9.04M.
  • Saturn V Capital Management fully exited Cogent Biosciences in Q2 2026, selling an estimated $24.1M.
  • Saturn V Capital Management's ten largest holdings make up 76% of its $697M portfolio in Q2 2026.
  • Saturn V Capital Management opened 3 new positions and closed 1 in Q2 2026.
  • Saturn V Capital Management's portfolio value rose 26% quarter-over-quarter to $697M.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.